Satellos to Highlight Duchenne Drug Program at Series of Investor Conferences

Satellos Bioscience ( (TSE:MSCL) ) has issued an announcement.

Satellos Bioscience said its management team will present at several high-profile healthcare investor conferences in late February and early March, including events hosted by Oppenheimer, TD Cowen and Leerink Partners, with presentations accessible via live webcast. The company will also hold one-on-one meetings with investors, using the conferences to spotlight progress in its SAT-3247 clinical program for Duchenne muscular dystrophy and to reinforce its positioning in the competitive muscle disease therapeutics space.

The most recent analyst rating on (TSE:MSCL) stock is a Buy with a C$16.00 price target. To see the full list of analyst forecasts on Satellos Bioscience stock, see the TSE:MSCL Stock Forecast page.

Spark’s Take on TSE:MSCL Stock

According to Spark, TipRanks’ AI Analyst, TSE:MSCL is a Neutral.

The score is held down primarily by weak financial performance (pre-revenue, large losses, and heavy cash burn with ongoing funding risk). Technicals are supportive due to a clear uptrend, but overbought signals temper that strength. Valuation is also constrained by negative earnings and no dividend support.

To see Spark’s full report on TSE:MSCL stock, click here.

More about Satellos Bioscience

Satellos Bioscience Inc. is a clinical-stage biotechnology company focused on developing drugs that restore natural muscle repair and regeneration in degenerative muscle diseases. Its lead candidate, SAT-3247, is an orally administered small molecule targeting AAK1 to help re-establish muscle stem-cell signaling, initially being developed as a potential disease-modifying treatment for Duchenne muscular dystrophy regardless of exon mutation status.

Average Trading Volume: 32,482

Technical Sentiment Signal: Buy

Current Market Cap: C$243.3M

See more data about MSCL stock on TipRanks’ Stock Analysis page.